

Journal Pre-proof

Effects of nifedipine and sildenafil on placental hemodynamics and gas exchange during fetal hypoxemia in a chronic sheep model

Leena Alanne, Amarnath Bhide, Jonna Hoffren, Juulia Lantto, Heikki Huhta, Merja Kokki, Mervi Haapsamo, Ganesh Acharya, Juha Räsänen



PII: S0143-4004(19)30725-8

DOI: <https://doi.org/10.1016/j.placenta.2019.12.014>

Reference: YPLAC 4073

To appear in: *Placenta*

Received Date: 29 September 2019

Revised Date: 11 December 2019

Accepted Date: 15 December 2019

Please cite this article as: Alanne L, Bhide A, Hoffren J, Lantto J, Huhta H, Kokki M, Haapsamo M, Acharya G, Räsänen J, Effects of nifedipine and sildenafil on placental hemodynamics and gas exchange during fetal hypoxemia in a chronic sheep model, *Placenta* (2020), doi: <https://doi.org/10.1016/j.placenta.2019.12.014>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier Ltd.

1 **Effects of nifedipine and sildenafil on placental hemodynamics and gas exchange during fetal**
2 **hypoxemia in a chronic sheep model**

3 Leena Alanne^a, Amarnath Bhide^{b,c}, Jonna Hoffren^a, Juulia Lantto^d, Heikki Huhta^e, Merja Kokki^f,
4 Mervi Haapsamo^g, Ganesh Acharya^{c,h}, Juha Räsänen^{d,i}

5 ^aDepartment of Obstetrics and Gynecology, Kuopio University Hospital and University of Eastern
6 Finland, Kuopio, Finland, ^b Department of Obstetrics and Gynecology, St. George's Hospital,
7 London, United Kingdom, ^c Women's Health & Perinatal Research Group, Department of Clinical
8 Medicine, UiT-The Arctic University of Norway, Tromsø, Norway, ^d Department of Obstetrics and
9 Gynecology, Oulu University Hospital and University of Oulu, Oulu, Finland, ^e Department of
10 Surgery, Oulu University Hospital, Oulu, Finland, ^f Department of Anesthesiology, Kuopio
11 University Hospital and University of Eastern Finland, Kuopio, Finland, ^g Department of Obstetrics
12 and Gynecology, Satakunta Central Hospital, Pori, Finland, ^h Department of Clinical Science,
13 Intervention & Technology, Karolinska Institute and Center for Fetal Medicine Karolinska
14 University Hospital, Stockholm, Sweden, ⁱ Department of Obstetrics and Gynecology, Helsinki
15 University Hospital and University of Helsinki, Helsinki, Finland.

16 Corresponding Author:

17 Juha Rasanen, MD, PhD

18 Department of Obstetrics and Gynecology

19 Helsinki University Hospital

20 PL 140, 00029 HUS, Helsinki, Finland

21 Tel. +358 50 3088694, Fax: +358 9 47174906

22 E-mail: juha.rasanen@oulu.fi

23

24

25

26

27

Highlights

2

3 • Sildenafil decreased fetal blood pressure and placental blood flow in hypoxemia.

4 • Nifedipine did not disturb placental blood flow in fetal hypoxemia.

5 • Umbilical artery vascular impedance did not reflect placental hemodynamic changes.

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

1 **Abstract**

2

3 **Introduction:** We hypothesized that nifedipine and sildenafil would have no detrimental effects on
4 placental hemodynamics and gas exchange under fetal hypoxemia.

5 **Methods:** In 33 chronically instrumented fetal sheep, placental volume blood flow (Q_{Plac}) and
6 umbilical artery (UA) vascular impedance were measured by Doppler ultrasonography. Fetal
7 carotid artery blood pressure and blood gas values were monitored. After baseline data collection,
8 maternal and fetal hypoxemia were induced. Following hypoxemia phase data collection, 12 fetuses
9 received sildenafil and 9 fetuses nifedipine infusion, and 12 fetuses served as controls receiving
10 saline infusion. Data were collected 30 and 120 minutes after infusion was started. Then maternal
11 oxygenation was normalized and normoxemia phase data were collected, while infusion was
12 continued.

13 **Results:** Hypoxemia significantly decreased fetal pO_2 and blood pressure. In the sildenafil group at
14 30- and 120-minutes hypoxemia + infusion phases, fetal blood pressure and Q_{Plac} were significantly
15 lower and pCO_2 higher than at baseline without returning to baseline level at normoxemia +
16 infusion phase. In hypoxemia, nifedipine did not affect fetal blood pressure or placental
17 hemodynamics. Both in the sildenafil and nifedipine groups, fetal pO_2 remained significantly lower
18 at normoxemia + infusion phase than in the control group. Umbilical artery vascular impedance did
19 not change during the experiment.

20 **Discussion:** In fetal hypoxemia, sildenafil had detrimental effects on placental hemodynamics that
21 disturbed placental gas exchange. Nifedipine did not alter placental hemodynamics in hypoxemia
22 but disturbed placental gas exchange upon returning to normoxemia. Umbilical artery vascular
23 impedance did not reflect alterations in placental hemodynamics.

24 **Keywords:** blood flow; fetus; physiology; pregnancy; ultrasound

1 **Abbreviations:** Q_{Plac} , placental volume blood flow; UA, umbilical artery; PI, pulsatility index; UV,
2 umbilical venous; R_{Plac} , placental vascular resistance; MAP, mean arterial pressure; LMM, Linear
3 Mixed Model

4

5 **1. Introduction**

6 In pregnancies complicated by maternal hypertensive disorder, antihypertensive medication is often
7 indicated. Calcium channel blockers, i.e. nifedipine, are commonly used in pregnancy to control
8 maternal blood pressure. In addition, calcium channel blockers have a tocolytic effect on uterine
9 smooth muscle and therefore they are widely used to delay delivery in preterm labor ¹. It has been
10 shown that nifedipine does not lower fetal blood pressure ². However, there is some evidence that
11 nifedipine could impair uterine blood flow, potentially even resulting in fetal hypoxemia and
12 acidemia ³. In human pregnancies, studies have shown that maternal nifedipine administration
13 either does not change uterine artery hemodynamics or may cause a short-term decrease in uterine
14 artery vascular impedance, while umbilical artery vascular impedance is unaffected ^{4,5}.

15 Recently sildenafil citrate (sildenafil), an inhibitor of phosphodiesterase-5, has gained a lot of
16 interest, especially as a potential treatment in pregnancies complicated by early onset severe fetal
17 growth restriction and placental insufficiency. Sildenafil has shown promise in studies of fetal
18 growth restriction, preeclampsia, as well as in animal studies ⁶⁻¹³. However, recent randomized trials
19 revealed disappointing results suggesting that sildenafil does not prolong pregnancy or improve
20 pregnancy outcomes in severe early-onset fetal growth restriction ^{14,15}. There is even alarming
21 evidence that maternally administered sildenafil could be harmful to the newborns by increasing the
22 incidence of persistent pulmonary hypertension ¹⁶.

23 Both nifedipine ¹⁷ and sildenafil ¹⁸ cross the placenta with fetal concentrations close to those
24 observed in maternal blood. In addition, maternal hypertensive disorders are often associated with

1 placental insufficiency and suboptimal gas exchange exposing the fetus to hypoxemia. Therefore,
2 we developed a fetal sheep model to investigate the effects of nifedipine and sildenafil on placental
3 hemodynamics when fetus is hypoxemic. We hypothesized that nifedipine and sildenafil would not
4 detrimentally affect placental hemodynamics and gas exchange under hypoxemic conditions. The
5 specific aims of the present study were to explore the effects of nifedipine and sildenafil on 1) fetal
6 arterial blood pressure and placental volume blood flow, 2) fetal arterial blood gas values, and 3)
7 umbilical artery blood flow velocity waveform pattern.

8

9 **2. Materials and Methods**

10

11 The study protocol was reviewed and approved by the National Animal Experiment Board of
12 Finland (ESAVI/1007/04.10.07/ 2014). The animal care and experimental procedures were
13 conducted according to the national legislation¹⁹ and the EU Directive 2010/63/EU²⁰. A total of 33
14 sheep of Finnish breed with time-dated pregnancies were included in this study.

15 *2.1 Surgical protocol*

16 Sheep underwent surgery at 115-129 gestational days (term 145 days) for fetal instrumentation
17 under general anesthesia that was induced with intravenous Propofol (4–7 mg/kg) and maintained
18 with isoflurane (1.5–2.5%) in an oxygen–air mixture delivered via an endotracheal tube. Fentanyl
19 (0.05–0.15 mg) was given as intravenous boluses when required. After laparotomy, the fetal head
20 and neck were delivered through a small hysterotomy incision. Polyvinyl catheters were introduced
21 into the internal jugular vein and the carotid artery. A 3-lead 28-gauge silver coated copper
22 electrocardiogram wire (New England Wire Tech., Lisbon, NH) was inserted subcutaneously on the
23 fetal chest. A polyvinyl catheter was placed in the amniotic cavity to monitor intra-amniotic
24 pressure. The lost amniotic fluid was replaced with warm 0,9 % saline solution. All incisions were
25 closed and the fetus received an intra-amniotic injection of Penicillin G (1 million Units). All

1 catheters and wires were tunnelled to a pouch on the ewe's flank. Post-operative pain was
2 controlled with oxycodone given via epidural catheter that was placed to the ewe before the surgery.

3 *2.2 Experimental protocol*

4 Following a 4-5-day recovery period, at 119-133 gestational days, the experiments were performed
5 under general anesthesia induced with propofol and maintained by isoflurane in an oxygen/air
6 mixture. A 16-gauge polyurethane catheter was inserted into the maternal femoral artery.
7 Anesthesia was titrated to minimize its effect on maternal heart rate and blood pressure and allow
8 for ultrasound examination without discomfort. The ewe was placed supine with a right lateral tilt
9 and allowed to stabilize for 30 minutes before obtaining the baseline measurements. Thereafter, the
10 ewe was connected to a re-breathing circuit to induce maternal and fetal hypoxemia. Maternal FiO_2
11 was reduced to reach the oxygen saturation level of 80%. This was verified by maternal arterial
12 blood gas values. Hypoxemia phase data (hypoxemia) were collected 30 minutes after desired
13 maternal oxygen saturation level was reached. After hypoxemia data collection, 12 fetuses were
14 allocated to receive sildenafil infusion into the internal jugular vein (sildenafil citrate 0.8mg/ml) that
15 was diluted 1:1 in saline and infused at a rate of 2.5ml/h (1.0mg/h). The sildenafil dose was selected
16 from the study by Jaillard et al ²². Nine fetuses were allocated to receive nifedipine infusion at a rate
17 of 1.0 ml/h (700 $\mu\text{g/ml}$) (5 $\mu\text{g/kg/min}$). The nifedipine dose was based on the studies by Blea et al ²
18 and Nugent et al ²³. The control group consisted of 12 fetuses that received saline infusion,
19 respectively. Data were collected at 30 (hypoxemia + 30 min) and 120 (hypoxemia + 120 min)
20 minutes following commencement of infusion. After hypoxemia+120 min infusion data collection
21 was completed, maternal oxygenation was returned to baseline level while infusion was continued.
22 Maternal normoxemia was achieved within 1-3 minutes. Recovery phase data collection
23 (normoxemia + infusion) was started 30 minutes after maternal normoxemia was restored (Figure
24 1). The infusion time was about 150 minutes in each group, and the calculated total mean dose of
25 sildenafil was 2.5 mg and that of nifedipine was 1.75 mg, respectively. The animals were

1 euthanised at the end of the experiment with an intravenous overdose (100 mg/kg) of pentobarbital
2 sodium to the fetus and ewe. Fetal weights were determined postmortem.

3 *2.3 Monitoring protocol*

4 Maternal and fetal blood pressures were continuously monitored with disposable pressure
5 transducers (DT-XX, Ohmeda, Hatfield, UK). Fetal arterial and venous blood pressures were
6 referenced to intra-amniotic pressure. Heart rates were determined from the arterial pressure
7 waveforms. Fetal electrocardiogram leads were connected to the ultrasound equipment. Maternal
8 and fetal blood gas values were corrected to 39°C and analyzed at each study point using an Abbot
9 i-Stat 1 arterial blood gas analyzer (i-Stat, East Windsor, NJ, USA).

10 Doppler ultrasonography of placental hemodynamics was performed at the end of each phase by a
11 single investigator (J.R.) using the Vivid 7 Dimension ultrasound system (GE Vingmed Ultrasound,
12 Horten, Norway) with a 10 MHz-phased array transducer. The high-pass filter was set at minimum,
13 and the angle of insonation was kept below 15 degrees. Umbilical artery pulsatility index (PI)
14 values were calculated ($[\text{peak systolic velocity} - \text{end diastolic velocity}] / \text{time-averaged maximum}$
15 $\text{velocity over the cardiac cycle}$). Three consecutive cardiac cycles were measured, and the mean
16 value was used for further analysis. Placental volume blood flow (Q_{plac}) was estimated by
17 calculating umbilical venous (UV) volume blood flow as follows: $0,5 \times \text{UV maximum velocity}$
18 $(\text{cm/s}) \times \pi (\text{UV diameter (cm)}/2)^2 \times 60$.²¹ Placental volume blood flow was weight indexed.

19 Placental vascular resistance (R_{plac}) was calculated by dividing fetal MAP by Q_{plac} .

20 *2.4 Statistical analysis*

21
22 Linear Mixed Model (LMM) was used for repeatedly measured data. Phase of the experiment and
23 treatment versus saline were included as fixed effects, an interaction term, and individual fetus as
24 random intercept. If LMM showed a significant difference between measurement points ($p(\text{time}) <$
25 0.05), then a pairwise comparison between relevant points was performed. Difference between the

1 groups was expressed as p(group). The groups may not show similar changes with time (interaction
2 term). Therefore, this was expressed as p(group*time). Statistical analyses were performed using
3 SPSS (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 25. Armonk, NY:
4 IBM Corp.). Data are presented as mean and standard deviation (SD) unless stated otherwise. Two-
5 tailed p value < 0.05 was considered statistically significant.

6

7 3. Results

8

9 The experiments were performed at the mean (SD) gestational age of 128 (2), 126 (5) and 128 (3)
10 days in the control, nifedipine and sildenafil groups (F=0.88, p=0.42). Maternal weight was
11 comparable between the groups. Maternal heart rate and blood pressures did not differ between the
12 groups during the experiment (data not shown). Mean (SD) fetal weight was 2.44 (0.28), 2.52 (0.24)
13 and 2.38 (0.34) kg in the control, nifedipine and sildenafil groups (F=0.58, p=0.56).

14 During hypoxemia phase, fetal pO₂ and mean arterial pressure (MAP) decreased significantly
15 compared to baseline with no difference between the groups. Other fetal blood gas values, as well
16 as placental hemodynamic parameters and UA PI values were comparable to baseline (Tables 1 and
17 2).

18 At hypoxemia + 30 min infusion and hypoxemia + 120 min infusion phases, fetal MAP and weight-
19 indexed Q_{Plac} were significantly lower compared to baseline in the sildenafil group (Table 2,
20 Figures 2 and 3). Weight-indexed R_{Plac} did not change significantly. Furthermore, fetal pCO₂
21 increased significantly at hypoxemia + 120 min infusion phase in the sildenafil group (Table 1). In
22 the control and nifedipine groups, fetal MAP, placental hemodynamic parameters and pCO₂
23 remained stable during the hypoxemia + infusion phases. In addition, in each group, fetal pH and
24 base excess decreased and lactate concentration increased significantly during hypoxemia +

1 infusion phases with no differences between the groups. Umbilical artery PI values did not change
2 during the hypoxemia + infusion phases in any of the groups.

3 During normoxemia + infusion phase, fetal MAP and Q_{Plac} remained significantly lower and fetal
4 pCO_2 higher than at baseline in the sildenafil group (Table 2, Figures 2 and 3). In addition, in the
5 sildenafil group fetal pCO_2 was significantly higher than in the control and nifedipine groups. At
6 normoxemia + infusion phase, fetal pO_2 values remained significantly lower in the sildenafil and
7 nifedipine groups than in the control group (Table 1). Fetal pH, base excess and lactate values were
8 lower than at baseline in each group. Umbilical artery PI values and R_{Plac} were comparable to
9 baseline values with no difference between the groups.

10

11 **4. Discussion**

12 In the present study using a chronically instrumented sheep model with intact placental circulation
13 and fetal hypoxemia, we found that sildenafil, when given directly to the fetus, significantly
14 decreased fetal arterial blood pressure and placental volume blood flow that were associated with a
15 rise in fetal pCO_2 indicating abnormal placental perfusion. On the other hand, fetal nifedipine
16 infusion did not significantly alter placental volume blood flow or fetal arterial blood pressure.
17 However, during normoxemia + infusion phase fetal pO_2 did not return to baseline level in
18 nifedipine and sildenafil groups. Despite significant changes in fetal blood gas values, placental
19 volume blood flow and fetal blood pressure in the sildenafil group, umbilical artery vascular
20 impedance did not reflect any of these alterations.

21 Both sildenafil and nifedipine cross the placenta and their concentrations in fetal blood are close to
22 those values in maternal blood. In the present study, we wanted to explore the direct effects of
23 sildenafil and nifedipine on the fetoplacental circulation rather than those secondary to changes in
24 maternal hemodynamics. Therefore, we decided to give both drugs directly into the fetal circulation

1 during hypoxemia in relevant concentrations^{22,23}. Previously, we have shown that fetal sildenafil
2 infusion does not alter cardiac function or central hemodynamics in hypoxemia²⁴. Experimental
3 studies have shown that umbilicoplacental circulation has no significant autoregulative capacity and
4 perfusion pressure has a critical role in the maintenance of placental volume blood flow²⁵.
5 Therefore, a drop in fetal arterial blood pressure can have a profound detrimental effect on placental
6 volume blood flow and gas exchange. On the other hand, it has been shown that sildenafil infusion
7 into the fetal circulation did not affect fetal arterial blood pressure under normoxemic environment
8²². In addition, a previous sheep study with fetal intrauterine growth restriction induced by single
9 umbilical artery ligation showed that maternally administered sildenafil significantly reduced
10 uterine blood flow and decreased fetal pO₂ as well as arterial blood pressure²⁶. We propose that
11 sildenafil could interfere with hypoxemia induced fetal peripheral chemoreflex causing a drop in
12 fetal blood pressure and placental volume blood flow. Altogether, evidence from experimental
13 studies including the present study point out that sildenafil can have significant detrimental effects
14 on both utero- and umbilicoplacental hemodynamics, even with intact placental circulation.

15 We did not find any significant change in fetal arterial blood pressure or placental volume blood
16 flow during nifedipine infusion under fetal hypoxemia. However, during normoxemia + infusion
17 phase fetal pO₂ remained lower than in the control group. Our observations are in agreement with a
18 study that found only a transient reduction in uteroplacental blood flow with no change in
19 fetoplacental blood flow by using radioactively-labeled microsphere technique when nifedipine was
20 administered to the ewe². In addition, nifedipine did not alter volume blood flows and vascular
21 resistances of the fetal organs, except for the adrenal blood flow that increased during nifedipine
22 administration. However, conflicting results have been reported. Maternal nifedipine infusion has
23 been shown to increase fetal lung and skeletal muscle blood flow, while blood flow to carcass
24 decreases, suggesting a redistribution of fetal circulation²⁷. In addition, significant increases in total
25 and regional fetal cerebral blood flow have been demonstrated with maternal nifedipine infusion³.

1 It seems that at least some of these hemodynamic changes are related to nifedipine dose, because
2 with higher doses also a reduction in uterine blood flow and fetal arterial oxygen content have been
3 demonstrated ³. In the present study, nifedipine infusion did not alter fetal blood gas values during
4 hypoxemia, most likely reflecting mean arterial blood pressure and placental volume blood flow
5 that were maintained comparable to the control group fetuses. Interestingly in nifedipine group,
6 upon returning to normoxemia + infusion phase, fetal pO₂ did not return to baseline level that was
7 observed in the control group fetuses. This finding is similar to that published previously ². The
8 authors observed fetal acidosis and hypoxia without evident temporal blood flow changes and a
9 relative lack of maternal hemodynamic changes strongly suggesting that other fetal metabolic
10 mechanisms could explain this finding. It has been speculated that local discrepancies in placental
11 metabolism caused by cellular calcium entry blockade or increased fetal oxygen utilization could
12 lead to decreased arterial oxygen content ².

13 Sildenafil and nifedipine had no significant effect on umbilical artery PI values. This agrees with a
14 study, in which fetal growth restriction was induced by uterine artery embolization ²⁸. In a group
15 with uterine artery embolization and maternal sildenafil, umbilical artery resistance index values
16 were comparable to the control group fetuses. In contrast, clinical studies on human pregnancies
17 complicated by maternal preeclampsia or intrauterine fetal growth restriction have reported
18 improvement in the umbilical artery blood flow velocity waveform during maternal sildenafil
19 therapy ^{6, 8, 9}. Our findings with significantly reduced placental volume blood flow, disturbed gas
20 exchange and significant fetal metabolic acidosis combined with unaffected umbilical artery PI
21 demonstrate the limitations of umbilical artery blood flow velocity waveform to detect significant
22 changes in placental circulatory physiology.

23 Our experimental study has several clinical implications. Maternally administered vasoactive agents
24 can also affect fetal and placental circulatory physiology. Sildenafil has shown some promise in the
25 treatment of severe early-onset placental insufficiency. However, recent data suggests that sildenafil

1 when administered during pregnancy could increase the incidence of persistent pulmonary
2 hypertension in newborns ¹⁶. We designed this study to explore the effects of sildenafil and
3 nifedipine on placental hemodynamics under hypoxemic conditions. Fetal hypoxemia often
4 complicates severe placental insufficiency. The observations that sildenafil decreases fetal arterial
5 blood pressure and placental volume blood flow and disturbs gas exchange are clinically important.
6 These detrimental alterations occurred even in the presence of histologically unaffected placental
7 circulation. Placental insufficiency is usually associated with reduced tertiary villous artery
8 capacity. Furthermore, our study shows that the effects of vasoactive drugs on placental circulatory
9 physiology cannot be explored by only investigating umbilical artery vascular impedance.

10 STRIDER trials conducted in different countries have revealed partially inconsistent results, but
11 especially concerning possible harmful effects of in utero exposure to sildenafil on newborn
12 pulmonary circulatory physiology ^{14, 16}. This becomes even more clinically important, because
13 animal studies suggest that in fetal congenital diaphragmatic hernia in utero sildenafil improves
14 lung vasculature ²⁹. However, in fetuses without diaphragmatic hernia sildenafil can reduce
15 pulmonary vascular branching. Therefore, more understanding about the action of sildenafil in
16 different pregnancy complications is urgently needed. Furthermore, as our study shows, umbilical
17 artery blood flow velocity waveform has a limited capacity to reflect changes in the placental
18 circulatory physiology. Future studies exploring the possible drug effects on placental
19 hemodynamics should consider the results of the present study.

20 **5. Limitations**

21 The fetuses underwent surgical intervention that could constitute a major stress. However, the
22 recovery period after surgery is long enough for recovery of fetal circulatory physiology as
23 evidenced by normal blood gas values at baseline ³⁰. We performed the experiments under general
24 anesthesia that could modify fetal cardiovascular adaptation. There is evidence that cardiovascular
25 system of the newborn lamb can increase oxygen delivery in response to hypoxemic stress during

1 isoflurane anesthesia. Therefore, at reasonable anesthetic depth, and without myocardial or
2 peripheral cardiovascular disease, the newborn lamb can coordinate neural, endocrine, and local
3 tissue responses to increase cardiovascular performance in response to hypoxemia³¹. There are
4 some differences in placental circulatory physiology and anatomy between human and sheep
5 fetuses. However, sheep experiments have provided invaluable information on placental
6 hemodynamics. Validation studies in sheep fetuses have proven that invasive and Doppler
7 echocardiographic volume blood flow calculations correlate well³². The intraobserver variabilities
8 of Doppler ultrasonographic parameters of fetal sheep cardiovascular hemodynamics are
9 comparable to those found in human fetuses during the second half of pregnancy^{33,34}.

10 **6. Conclusions**

11 Our study shows that in hypoxemic fetus with intact placental circulation, sildenafil had detrimental
12 effects on placental hemodynamics by decreasing fetal blood pressure and placental volume blood
13 flow that led to disturbed placental gas exchange. On the other hand, under fetal hypoxemia
14 nifedipine did not alter placental hemodynamics. However, it disturbed placental gas exchange
15 when oxygenation was normalized. Umbilical artery vascular impedance did not change despite
16 significant alterations in placental hemodynamics.

17 **Conflicts of interest**

18 None declared.

19 **Acknowledgements**

20 This work was supported by the regional authority of Northern Norway (project no 12050).

21 **Author contributions**

22 LA - Acquisition, analysis or interpretation of data for the work, drafting the manuscript

- 1 AB - Acquisition, analysis or interpretation of data for the work, revising it critically for
2 important intellectual content
- 3 JH - Acquisition, analysis or interpretation of data for the work, drafting the manuscript
- 4 JL - Acquisition, analysis or interpretation of data for the work, revising the manuscript critically
5 for important intellectual content
- 6 HH - Acquisition, analysis or interpretation of data for the work, revising the manuscript critically
7 for important intellectual content
- 8 MK - Acquisition, analysis or interpretation of data for the work, revising the manuscript critically
9 for important intellectual content
- 10 MH - Acquisition, analysis or interpretation of data for the work, revising the manuscript critically
11 for important intellectual content
- 12 GA - Conception and design of the work, acquisition, analysis and interpretation of data for
13 the work, revising it critically for important intellectual content
- 14 JR - Conception and design of the work, acquisition, analysis and interpretation of data for
15 the work, revising it critically for important intellectual content
- 16 • All the authors approved the final version of the manuscript.
- 17 • All the authors agree to be accountable for all aspects of the work in ensuring that
18 questions related to the accuracy or integrity of any part of the work are
19 appropriately investigated and resolved
- 20 • All persons designated as authors qualify for authorship, and all those who qualify
21 for authorship are listed

1

2 **References**3 1. Smith P, Anthony J, Johanson R. Nifedipine in pregnancy. *BJOG* 2000;107:299-307.4 2. Blea, CW, Barnard, JM, Magness, RR, Phernetton, TM, Hendricks, SK. Effect of nifedipine on
5 fetal and maternal hemodynamics and blood gases in the pregnant ewe. *Am J Obstet*
6 *Gynecol* 1997;176:922-30.7 3. Harake B, Gilbert RD, Ashwal S, Power GG. Nifedipine: Effects on fetal and maternal
8 hemodynamics in pregnant sheep. *Am J Obstet Gynecol* 1987;157:1003-8.9 4. Guclu S, Gol M, Saygili U, Demir N, Sezer O, Baschat AA. Nifedipine therapy for preterm labor:
10 effects on placental, fetal cerebral and atrioventricular Doppler parameters in the first 48 hours.
11 *Ultrasound Obstet Gynecol* 2006;27:403-8.12 5. Ulubasoglu H, Özmen Bayar U, Kaya C, Urgan B. The effect of nifedipine tocolysis on Doppler
13 indices of the uterine and umbilical arteries. *J Clin Ultrasound* 2015;43:322-6.14 6. Dastjerdi MV, Hosseini S, Bayani L. Sildenafil citrate and uteroplacental perfusion in fetal
15 growth restriction. *J Res Med Sci* 2012;17:632-6.16 7. von Dadelszen P, Dwinnell S, Magee LA, et al. Sildenafil citrate therapy for severe early-onset
17 intrauterine growth restriction. *BJOG* 2011;118:624-8.18 8. El-Sayed MA, Saleh SA, Maher MA, Khidre AM. Utero-placental perfusion Doppler indices in
19 growth restricted fetuses: effect of sildenafil citrate. *J Matern Fetal Neonatal Med* 2018;31:1045-50.20 9. Trapani A Jr, Goncalves LF, Trapani TF, Franco MJ, Galluzzo RN, Pires MM. Comparison
21 between transdermal nitroglycerin and sildenafil citrate in intrauterine growth restriction: Effects on

- 1 uterine, umbilical and fetal middle cerebral artery pulsatility indices. *Ultrasound Obstet Gynecol*
2 2016;48:61-5.
- 3 10. Samangaya RA, Mires G, Shennan A, et al. A randomised, double-blinded, placebo-controlled
4 study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia.
5 *Hypertension in Pregnancy* 2009;28:369-82.
- 6 11. Trapani A Jr, Goncalves LF, Trapani TF, Vieira S, Pires M, Pires MM. Perinatal and
7 hemodynamic evaluation of sildenafil citrate for preeclampsia treatment: A randomized controlled
8 trial. *Obstet Gynecol*. 2016;128:253-9.
- 9 12. Wareing M, Myers JE, O'Hara M, Baker PN. Sildenafil citrate (viagra) enhances vasodilatation
10 in fetal growth restriction. *J Clin Endocrinol Metab* 2005;90:2550-5.
- 11 13. Stanley JL, Andersson IJ, Poudel R, et al. Sildenafil citrate rescues fetal growth in the catechol-
12 O-methyl transferase knockout mouse model. *Hypertension* 2012;59:1021-8.
- 13 14. Sharp A, Cornforth C, Jackson R, et al. Maternal sildenafil for severe fetal growth restriction
14 (STRIDER): A multicentre, randomised, placebo-controlled, double-blind trial. *Lancet Child*
15 *Adolesc Health*. 2018;2:93-102.
- 16 15. Groom KM, McCowan LM, Mackay LK, et al. STRIDER NZAus: a multicentre randomised
17 controlled trial of sildenafil therapy in early-onset fetal growth restriction. *BJOG* 2019 Feb 19.
- 18 16. Groom KM, Ganzevoort W, Alfirovic Z, Lim K, Papageorghiou AT. Clinicians should stop
19 prescribing sildenafil for fetal growth restriction (FGR): Comment from the STRIDER consortium.
20 *Ultrasound Obstet Gynecol* 2018;52:295-6.
- 21 17. Prevost RR, Akl SA, Whybrew WD, Sibai BM. Oral nifedipine pharmacokinetics in pregnancy-
22 induced hypertension. *Pharmacotherapy* 1992;12:174-7.

- 1 18. Russo FM, Conings S, Allegaert K, et al. Sildenafil crosses the placenta at therapeutic levels in
2 a dually perfused human cotyledon model. *Am J Obstet Gynecol* 2018;219:619.e1-e10.
- 3 19. Finnish Government. Decree on the Protection of Animals Used for Scientific or Educational
4 Purposes. 564/2013.
- 5 20. The European Parliament and the Council of the European Union. Directive 2010/63/EU of the
6 European Parliament and of the Council on the protection of animals used for scientific purposes,
7 2010.
- 8 21. Acharya G, Wilsgaard T, Rosvold Berntsen G K, Maltau JM, Kiserud T. Reference ranges for
9 umbilical vein blood flow in the second half of pregnancy based on longitudinal data. *Prenatal
10 Diagnosis* 2005; 25:99-111.
- 11 22. Jaillard S, Larrue B, Deruelle P, et al. Effects of phosphodiesterase 5 inhibitor on pulmonary
12 vascular reactivity in the fetal lamb. *Ann Thorac Surg* 2006;81:935-42.
- 13 23. Nugent CE, Hill M, Hursey T, Abramson FP. Pharmacokinetics and pharmacodynamics of
14 nifedipine in pregnant sheep. *Drug Metab Dispos* 1991;19:754-7.
- 15 24. Bhide A, Alanne L, Rasanen J, et al. Effect of sildenafil on pulmonary circulation and
16 cardiovascular function in near-term fetal sheep during hypoxemia. *Reprod Sci* 2019; 26:337-47.
- 17 25. Berman W Jr, Goodlin RC, Heymann MA, Rudolph AM. Relationships between pressure and
18 flow in the umbilical and uterine circulations of the sheep. *Circ Res* 1976;38:262-6.
- 19 26. Miller SL, Loose JM, Jenkin G, Wallace EM. The effects of sildenafil citrate (viagra) on uterine
20 blood flow and well being in the intrauterine growth-restricted fetus. *Am J Obstet Gynecol*
21 2009;200:102.e1-e7.

- 1 27. Princzkel E, Vojcek L, Lampé LG, Turnbull AC. The redistribution of the blood flow under
2 nifedipine treatment in the sheep foetuses. *Acta Paediatr Hung* 1991;31:321-36.
- 3 28. Oyston C, Stanley JL, Oliver MH, Bloomfield FH, Baker PN. Maternal Administration of
4 Sildenafil Citrate Alters Fetal and Placental Growth and Fetal-Placental Vascular Resistance in the
5 Growth-Restricted Ovine Fetus. *Hypertension* 2016;68:760-7.
- 6 29. Mous DS, Kool HM, Buscop-van Kempen MJ, et al. Clinically relevant timing of antenatal
7 sildenafil treatment reduces pulmonary vascular remodeling in congenital diaphragmatic hernia.
8 *Am J Physiol Lung Cell Mol Physiol* 2016;311:L734-42.
- 9 30. De Muylder X, Fouron JC, Bard H, Urfer FN. Changes in the systolic time intervals of the fetal
10 heart after surgical manipulation of the fetus. *Am J Obstet Gynecol* 1983;147:285-8.
- 11 31. Brett CM, Teitel DF, Heymann MA, Rudolph AM. The young lamb can increase cardiovascular
12 performance during isoflurane anesthesia. *Anesthesiology* 1989;71:751-6.
- 13 32. Schmidt KG, Di Tommaso M, Silverman NH, Rudolph AM. Doppler echocardiographic
14 assessment of fetal descending aortic and umbilical blood flows. validation studies in fetal
15 lambs. *Circulation* 1991;83:1731-7.
- 16 33. Bernard LS, Hashima JN, Hohimer AR, et al. Myocardial performance and its acute response to
17 angiotensin II infusion in fetal sheep adapted to chronic anemia. *Reproductive Sciences* 2012;19:
18 173-80.
- 19 34. Rasanen J, Wood DC, Debbs RH, Cohen J, Weiner S, Huhta JC. Reactivity of the human fetal
20 pulmonary circulation to maternal hyperoxygenation increases during the second half of pregnancy:
21 A randomized study. *Circulation* 1998;97:257-62.

Table 1. Fetal arterial blood gas parameters

Parameter	Baseline	Hypoxemia	Group	Hypoxemia + 30 min infusion	Hypoxemia + 120 min infusion	Normoxemia + infusion	Group <i>p</i> - value	Time <i>p</i> - value	Group x time <i>p</i> - value
pO₂ (kPa)			C	1.5 (0.4)	1.5 (0.2)	2.8 (0.4)			
	2.8 (0.6)	1.6 (0.4)	N	1.6 (0.4)	1.6 (0.5)	2.3 (0.3)*	0.59	0.001	0.030
			S	1.5 (0.3)	1.5 (0.5)	2.1 (0.4)**			
Base excess (mmol/l)			C	-7.0 (5.1)	-10.2 (6.0)	-9.0 (3.6)			
	-1.4 (3.4)	1.9 (3.2)	N	-6.0 (6.1)	-8.9 (5.5)	-7.3 (4.8)	0.99	0.001	0.57
			S	-6.1 (4.6)	-11.6 (7.6)	-10.6 (7.9)			
pH			C	7.21 (0.11)	7.15 (0.12)	7.18 (0.06)			
	7.29 (0.05)	7.28 (0.05)	N	7.21 (0.11)	7.14 (0.14)	7.19 (0.10)	0.54	0.001	0.72
			S	7.19 (0.08)	7.06 (0.16)	7.09 (0.16)			
Lactate (mmol/l)			C	7.7 (3.5)	9.7 (4.0)	9.6 (4.0)			
	0.4 (0.2)	0.5 (0.4)	N	7.5 (2.8)	10.4 (3.4)	10.4 (3.5)	0.97	0.001	0.59
			S	6.4 (3.0)	10.3 (4.0)	10.8 (4.6)			
pCO₂ (kPa)			C	6.9 (0.8)	7.0 (1.0)	6.8 (0.4)			
	7.0 (1.1)	7.0 (0.8)	N	7.1 (0.7)	7.8 (1.5)	7.3 (1.0)	0.007	0.001	0.41
			S	7.7 (1.0)	8.7 (2.4)**	8.4 (1.1)*			

Values are mean and (SD). Group *p*-value indicates the level of difference between the control (C), nifedipine (N) and sildenafil (S) groups, Time *p*-value indicates the change in measurements over time. Group x time *p*-value indicates the group x time interaction. *= <0.05 between groups in pairwise comparisons, **= <0.005 between groups in pairwise comparisons.

Table 2. Fetal heart rate, blood pressure and placental hemodynamic parameters.

Parameter	Baseline	Hypoxemia	Group	Hypoxemia + 30 min infusion	Hypoxemia + 120 min infusion	Normoxemia + infusion	Group <i>p</i> - value	Time <i>p</i> - value	Group x time <i>p</i> - value
Heart rate (bpm)	171 (27)	168 (27)	C	162 (27)	176 (16)	144 (25) ^α	0.72	0.004	0.49
			N	156 (22)	158 (32)	159 (28)			
			S	159 (20)	150 (42)	138 (35) ^α			
MAP (mmHg)	40 (8)	36 (7)	C	38 (13)	35 (9)	39 (7)	0.53	0.001	0.07
			N	36 (4)	32 (7)	32 (5)			
			S	33 (8)	28 (5)	28 (6)*			
Qplac (ml/min/kg)	85 (34)	73 (33)	C	66 (32)	64 (29)	67 (15)	0.81	0.001	0.81
			N	64 (28)	62 (25)	64 (32)			
			S	55 (20) ^α	52 (13) ^α	55 (20) ^α			
Rplac (mmHg/ ml/min / kg)	0.54 (0.22)	0.61 (0.30)	C	0.67 (0.33)	0.67 (0.39)	0.61 (0.20)	0.93	0.08	0.93
			N	0.75 (0.50)	0.60 (0.25)	0.58 (0.22)			
			S	0.69 (0.33)	0.60 (0.15)	0.62 (0.30)			
UA PI	1.6 (1.6)	1.7 (1.0)	C	2.8 (3.2)	2.4 (1.5)	2.2 (1.3)	0.08	0.15	0.46
			N	1.7 (0.4)	1.7 (0.5)	1.7 (0.5)			
			S	1.5 (0.3)	1.6 (0.5)	1.6 (0.7)			

Values are mean (SD). Group p-value indicates the level of difference between the control (C), nifedipine (N) and sildenafil (S) groups, Time p-value indicates the change in measurements over time. Group x time p-value indicates the group x time interaction. *= <0.05 between groups in pairwise comparisons. α ($p<0.05$) comparison to baseline. *MAP*, mean arterial pressure; *Qplac*, placental volume blood flow; *Rplac*, placental vascular resistance; *UA PI*, Umbilical artery pulsatility index.


Journal Pre-proof

Figure legends:

Figure 1. Timeline of the experiment

Figure 2. Fetal mean arterial pressure (MAP) during the experiment. Data are presented as mean (SD). α Indicates significant difference ($p < 0.001$) to baseline in the sildenafil group. * Indicates significant difference between the control and sildenafil groups ($p = 0.03$).

Figure 3. Weight-indexed placental volume blood flow (Q_{plac}) during the experiment. Data are presented as mean (SD). α Indicates significant difference ($p = 0.007$) to baseline in the sildenafil group.







Figure 1. Timeline of the experiment



Alanne et al; Effects of nifedipine and sildenafil on placental hemodynamics and gas exchange during fetal hypoxemia in a chronic sheep model

Highlights

- Sildenafil decreased fetal blood pressure and placental blood flow in hypoxemia.
- Nifedipine did not disturb placental blood flow in fetal hypoxemia.
- Umbilical artery vascular impedance did not reflect placental hemodynamic changes.

Alanne et al; Effects of nifedipine and sildenafil on placental hemodynamics and gas exchange during fetal hypoxemia in a chronic sheep model

Conflicts of interest

None declared.

Journal Pre-proof